VVT Medical’s ScleroSafe to Be Marketed by Methapharm in the United States

January 29, 2024—V.V.T. Med Ltd. (VVT Medical) recently announced the signing of a strategic distribution agreement with Methapharm Inc. for the marketing of VVT Medical’s ScleroSafe platform for varicose veins treatment in the United States. VVT Medical is an Israel-based developer of products for minimally invasive nonthermal, nontumescent (NT-NT) procedures with both medical and aesthetic indications.

The ScleroSafe platform received FDA 510(k) clearance in June 2023. ScleroSafe utilizes a dual syringe technique.

According the VVT Medical, the collaboration allows the companies to share applications in the same procedure for efficient NT-NT treatment and management of varicosities in superficial veins. Methapharm has extensive expertise in varicose veins and relationships with key stakeholders and physicians in the United States.

Methapharm is a privately held specialty pharmaceutical company that focuses on the acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own products as well as partners with global companies to deliver a line of products in the United States and Canada.

“ScleroSafe holds the promise of transforming varicose vein treatment, providing patients with a safe, effective, and straightforward option,” commented Erez Tetro, CEO of VVT Medical, stated in the press release. “We have strong confidence in the positive influence our product can bring to the lives of many throughout the United States, and we consider Methapharm as the ideal collaborator to realize this vision.”

Craig Baxter, CEO of Methapharm, added, “We at Methapharm are very excited to form this strategic relationship with VVT Medical, and we look forward to adding ScleroSafe to our offerings. We believe it will contribute significantly to our efforts to continually offer the best possible patient care.”